VEDOLIZUMAB IS SUPERIOR TO ANTI-TUMOR NECROSIS FACTOR AGENTS AS A FIRST-LINE BIOLOGICAL AGENT BUT NOT AS A SECOND-LINE BIOLOGICAL AGENT IN MODERATE TO SEVERE ULCERATIVE COLITIS

被引：0
|
作者：
Pudipeddi, Aviv
Ko, Yanna
Paramsothy, Sudarshan
Leong, Rupert W.
机构：
来源：
GASTROENTEROLOGY | 2021年 / 160卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Fr519
引用
收藏
页码：S343 / S343
页数：1
相关论文
共 50 条
  • [31] Anastrozole: A well established second-line agent and viable first-line option for postmenopausal women with advanced breast cancer
    不详
    Drugs & Therapy Perspectives, 2002, 18 (1) : 1 - 4
  • [32] Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease
    Nunez-Gomez, Laura
    Mesonero-Gismero, Francisco
    Albillos-Martinez, Agustin
    Lopez-Sanroman, Antonio
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2018, 41 (09): : 576 - 582
  • [33] Oral isotretinoin is first-line treatment in severe nodular acne, with other agents indicated as second-line or adjunctive therapy
    Drugs & Therapy Perspectives, 2011, 27 (8) : 11 - 14
  • [34] Persistence Among Patients with Ulcerative Colitis Previously Treated with an Anti-Tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic Agent
    Zhdanava, Maryia
    Kachroo, Sumesh
    Boonmak, Paul
    Burbage, Sabree
    Schwartzbein, Samuel
    Godwin, Bridget
    Lefebvre, Patrick
    Pilon, Dominic
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S726 - S728
  • [35] FIRST-LINE AND SECOND-LINE BIOLOGICS IN THE MANAGEMENT OF MODERATE-SEVERE CROHN'S DISEASE: A GRADE-BASED APPROACH
    Singh, Siddharth
    Fumery, Mathurin
    Dulai, Parambir
    Murad, Mohammad
    Sandborn, William J.
    GASTROENTEROLOGY, 2017, 152 (05) : S592 - S592
  • [36] Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis -: Results from a large UK national cohort study
    Hyrich, Kimme L.
    Lunt, Mark
    Watson, Kath D.
    Symmons, Deborah P. M.
    Silman, Alan J.
    ARTHRITIS AND RHEUMATISM, 2007, 56 (01): : 13 - 20
  • [37] The conversion ofRASstatus in metastatic colorectal cancer patients after first-line biological agent treatment
    Arici, Serdar
    Hamdard, Jamshid
    Sakin, Abdullah
    Sengiz Erhan, Selma
    Atci, Muhammed Mustafa
    Cekin, Ruhper
    Saka, Burcu
    Kose, Emin
    Saydam, Tuba
    Geredeli, Caglayan
    Cihan, Sener
    Bilici, Ahmet
    COLORECTAL DISEASE, 2021, 23 (01) : 206 - 212
  • [38] Induction with infliximab and a plant-based diet as first-line (IPF) therapy for moderate-to-severe to severe ulcerative colitis
    Chiba, Mitsuro
    Nakane, Kunio
    Tsuji, Tsuyotoshi
    Tsuda, Satoko
    Ishii, Hajime
    Ohno, Hideo
    Watanabe, Kenta
    Ito, Mai
    Obara, Yu
    Komatsu, Masafumi
    Sugawara, Takeshi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 483 - 483
  • [39] Real-world experience and analyses of the performance of ixekizumab as first-line biologic agent versus second-line (or higher) biologic agent in the treatment of chronic plaque psoriasis
    Goon, Peter Kin Cho
    Lim, Hai-Yee
    Summerfield, Liz
    Banfield, Cedric Charles
    Sudhoff, Holger
    Mallett, Dick
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2021, 60 (08) : E319 - E320
  • [40] First-Line Biologic Treatment for Moderate-to-Severe Ulcerative Colitis: A Cost-per-Remission Decision Analysis
    Park, K. T.
    Yokomizo, Lauren
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S777 - S777
12345